

## Cipla EU to Invest EUR 15 million in Ethris, initiating a strategic collaboration

- **Cipla & Ethris partner for the development of mRNA-based therapies**

**Mumbai, India and Munich, Germany: December 29, 2022:** Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as "Cipla" today announced that its wholly-owned UK subsidiary, Cipla (EU) Limited ("Cipla EU") has signed definitive agreements for equity investment of EUR 15 million in Ethris GmbH ("Ethris"), a global leader in delivering mRNAs directly to the respiratory system including administration by inhalation.

The investment will facilitate a long-term strategic partnership between Cipla and Ethris for the development of messenger RNA (mRNA)-based therapies and fast-track Cipla's participation in the mRNA space, enabling it to provide access to cutting-edge solutions developed by Ethris for the developing countries.

A collaboration agreement is signed concurrently with the definitive agreement, which paves a path to market Ethris' innovative portfolio in Cipla's key emerging markets.

The transaction is expected to get completed within 60 days from the date of signing of the agreement or such other time-period as may be mutually agreed between the parties in writing and shall be subject to completion of necessary regulatory formalities.

**Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla,** said: "This collaboration accelerates our innovation journey and enables us to provide access to cutting-edge healthcare solutions to our patients. We expect mRNA-based therapies to be one of the key innovation levers for Cipla. This inhaled mRNA technology is a paradigm shift in the delivery mechanism and this partnership reinforces Cipla's strength in respiratory therapy in line with our aspiration of attaining global lung leadership."

**Dr. Carsten Rudolph, CEO of Ethris** stated: "We value this strategic relationship with Cipla that will build on our pioneering mRNA technology and our joint focus on bringing innovative treatments for respiratory diseases to patients. The investment supports the further development of our pipeline and our objective to leverage the power of mRNA-based therapeutics to treat a broad range of diseases."

### **About Cipla:**

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 86 markets. Cipla is the 3<sup>rd</sup> largest in pharma in India (IQVIA MAT November '22), 3<sup>rd</sup> largest in the pharma private market in South Africa (IQVIA MAT October '22) and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV

Cipla Ltd.

Regd. Office -Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400013, India.

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-Mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of "Caring for Life" and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders.

For more, please visit [www.cipla.com](http://www.cipla.com), or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

### **Media Contacts:**

#### **Corporate Communications**

Heena Kanal

E-Mail: [Heena.kanal@cipla.com](mailto:Heena.kanal@cipla.com)

#### **Investor Relations**

Naveen Bansal

E-Mail: [Investor.Relations@cipla.com](mailto:Investor.Relations@cipla.com)

### **About Ethris**

Ethris has paved a new path from genes to therapeutic proteins, using its proprietary messenger RNA technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilised mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines against viral infections, with the ultimate goal of improving patients' lives.

For more information, visit [www.ethris.com](http://www.ethris.com)

#### **For Ethris, please contact:**

Dr. Carsten Rudolph

+49 89 8955788 10

[rudolph@ethris.com](mailto:rudolph@ethris.com)

#### **Media Relations:**

Gretchen Schweitzer

Trophic Communications

+49 172 861 8540

[ethris@trophic.eu](mailto:ethris@trophic.eu)